stockrow
Saturday 7 November 2026
Export GENB’s income statement to Excel — free account
Generate Biomedicines, Inc.
GENB Healthcare Biotechnology
Generate Biomedicines, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.9 million, up 55.9% from fiscal 2024.
13.06
0.49
+3.90%
Follow GENB
Alert me
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+2 more quarters Free account |
P/S ratio |
66.60 | 0.00 | — | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(37.34) | (10.09) | — | (2.08) | |
P/B ratio |
4.74 | 1.58 | — | 0.00 | |
Price to Tangible BV |
4.74 | 1.58 | — | 0.00 | |
EV/Sales |
52.56 | 0.00 | — | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(4.40) | (0.77) | — | (0.47) | |
EV/FCF |
(3.11) | (0.91) | — | (0.46) | |
Quick Ratio |
8.08 | 8.85 | 2.70 | — | |
Current Ratio |
8.30 | 9.17 | 2.85 | — | |
Net Debt/EBITDA |
6.63 | 8.44 | 0.00 | 0.00 | |
Debt/Assets |
0.24% | 0.35% | 0.88% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.12 | 0.00 | — | — | |
Operating CF/Net income |
0.86 | 1.16 | 0.00 | 0.76 | |
Capex/Depreciation |
(23.24) | 19.58 | (0.34) | (60.86) | |
Interest Coverage |
(462.03) | (352.26) | — | (195.93) | |
Research and Development Expense of Revenue |
1,018.85% | 800.28% | — | 589.68% | |
Selling, General and Administrative Expense of Revenue |
215.36% | 187.21% | — | 104.10% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
130.47% | 88.52% | — | 54.17% | |
Graham Net Nets |
0.17 | 0.52 | — | (1.71) | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(30.53%) | (30.53%) | — | (30.53%) | |
Free Cash Flow Yield |
(25.41%) | (40.22%) | — | (102.57%) | |
Revenue per Share |
0.05 | 0.11 | — | 0.31 | |
Operating CF per Share |
(0.45) | (1.24) | 0.00 | (1.48) | |
Capex per Share |
(0.51) | 0.94 | 0.00 | (4.66) | |
Free Cash Flow per Share |
(0.97) | (0.30) | 0.00 | (6.14) | |
Cash per Share |
3.57 | 7.96 | 0.00 | 0.00 | |
Shareholders Equity per Share |
3.56 | 7.94 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.56 | 7.94 | 0.00 | 0.00 | |
Free Cash Flow |
(123.88) | (19.17) | (204.13) | (202.54) | |
Working Capital |
413.62 | 477.00 | 152.16 | — | |
Capital Expenditures |
(65.93) | 61.22 | (3.51) | (153.79) | |
Net Current Asset Value |
364.61 | 424.45 | (711.78) | 0.00 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
10.44 | (8.47) | 0.00 | 15.18 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Assets |
280.85 | 572.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026